Amneal Pharmaceuticals (AMRX) Payables: 2017-2025
Historic Payables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $731.8 million.
- Amneal Pharmaceuticals' Payables rose 9.05% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 11.99%. This contributed to the annual value of $735.5 million for FY2024, which is 27.66% up from last year.
- As of Q3 2025, Amneal Pharmaceuticals' Payables stood at $731.8 million, which was up 9.75% from $666.8 million recorded in Q2 2025.
- Over the past 5 years, Amneal Pharmaceuticals' Payables peaked at $735.5 million during Q4 2024, and registered a low of $467.4 million during Q1 2023.
- Its 3-year average for Payables is $622.6 million, with a median of $619.2 million in 2024.
- As far as peak fluctuations go, Amneal Pharmaceuticals' Payables dropped by 14.28% in 2021, and later grew by 28.45% in 2024.
- Amneal Pharmaceuticals' Payables (Quarterly) stood at $525.3 million in 2021, then climbed by 10.00% to $577.9 million in 2022, then fell by 0.31% to $576.1 million in 2023, then increased by 27.66% to $735.5 million in 2024, then climbed by 9.05% to $731.8 million in 2025.
- Its Payables stands at $731.8 million for Q3 2025, versus $666.8 million for Q2 2025 and $628.6 million for Q1 2025.